Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yazheng Zhao

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|April 2, 2024
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting systemQian Cheng, Xuan Shi, Yazheng Zhao, et al.
IEEE Transactions on Neural Networks and Learning Systems|January 12, 2026
Anomaly Subgraph Detection on Multiple Associated Attributed NetworksNannan Wu, Ying Sun, Yazheng Zhao, et al.
Therapeutic Advances in Drug Safety|August 2, 2024
Vonoprazan-associated <i>Clostridioides difficile</i> infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting SystemMengling Ouyang, Shupeng Zou, Qian Cheng, et al.
Frontiers in Pharmacology|July 19, 2024
A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databasesShupeng Zou, Mengling Ouyang, Yazheng Zhao, et al.
Biomedicines|January 8, 2025
IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting NomogramShupeng Zou, Mengling Ouyang, Qian Cheng, et al.
Expert Opinion on Drug Safety|December 18, 2024
Pulmonary toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real world study based on US food and drug administration adverse events reporting system (FAERS)Sichen Sun, Xuan Shi, Mengling Ouyang, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2024
Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without <i>Helicobacter pylori</i> Infection: A Systematic Review and Network Meta-AnalysisMengling Ouyang, Shupeng Zou, Qian Cheng, et al.
International Journal of Biological Sciences|February 5, 2020
Ophiopogon Saponin C1 Inhibits Lung Tumors by Stabilizing Endothelium Permeability via Inhibition of PKCδYuanyuan Zhang, Yazheng Zhao, Yan Wu, et al.
Expert Opinion on Drug Safety|February 2, 2025
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS databaseQian Cheng, JunSheng Qi, Shupeng Zou, et al.
Journal of Translational Medicine|June 30, 2017
Allergens in red ginseng extract induce the release of mediators associated with anaphylactoid reactionsLu Wang, Yazheng Zhao, Ye Yang, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|April 2, 2024
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting systemQian Cheng, Xuan Shi, Yazheng Zhao, et al.
IEEE Transactions on Neural Networks and Learning Systems|January 12, 2026
Anomaly Subgraph Detection on Multiple Associated Attributed NetworksNannan Wu, Ying Sun, Yazheng Zhao, et al.
Therapeutic Advances in Drug Safety|August 2, 2024
Vonoprazan-associated <i>Clostridioides difficile</i> infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting SystemMengling Ouyang, Shupeng Zou, Qian Cheng, et al.
Frontiers in Pharmacology|July 19, 2024
A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databasesShupeng Zou, Mengling Ouyang, Yazheng Zhao, et al.
Biomedicines|January 8, 2025
IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting NomogramShupeng Zou, Mengling Ouyang, Qian Cheng, et al.
Expert Opinion on Drug Safety|December 18, 2024
Pulmonary toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real world study based on US food and drug administration adverse events reporting system (FAERS)Sichen Sun, Xuan Shi, Mengling Ouyang, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2024
Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without <i>Helicobacter pylori</i> Infection: A Systematic Review and Network Meta-AnalysisMengling Ouyang, Shupeng Zou, Qian Cheng, et al.
International Journal of Biological Sciences|February 5, 2020
Ophiopogon Saponin C1 Inhibits Lung Tumors by Stabilizing Endothelium Permeability via Inhibition of PKCδYuanyuan Zhang, Yazheng Zhao, Yan Wu, et al.
Expert Opinion on Drug Safety|February 2, 2025
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS databaseQian Cheng, JunSheng Qi, Shupeng Zou, et al.
Journal of Translational Medicine|June 30, 2017
Allergens in red ginseng extract induce the release of mediators associated with anaphylactoid reactionsLu Wang, Yazheng Zhao, Ye Yang, et al.
Pageof 2